Charles River to Buy Frontage Bioanalysis in $470 Million Cash Deal

The Tip Desk · November 9, 2026 · 3 min read

The contract research lab is taking Frontage private with Tigermed and Dr. Song Li, then carving out Exton clinical bioanalysis and DMPK sites to lift its clinical share of a market it said is due to reach $8 billion to $9 billion by 2031.

Charles River Laboratories International, Inc. (CRL) entered definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, subject to customary closing adjustments, plus additional payments of up to $75 million contingent on future performance of the acquired businesses.

The contract research lab said the deal is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals and other customary closing conditions. Charles River is participating in a consortium with Hongkong Tigermed Co., Limited, a subsidiary of Hangzhou Tigermed Consulting Co., Ltd., and Dr. Song Li to first take Frontage private, after which Frontage will be restructured and Charles River will ultimately own the assets and liabilities related to its bioanalysis and DMPK businesses in Exton. The three parties formed an acquisition vehicle that will privatize Frontage, listed on The Stock Exchange of Hong Kong Limited, by way of a court-sanctioned scheme of arrangement, following which Frontage’s listing will be withdrawn. Immediately after the privatization, the parties will separate Frontage’s businesses into subsidiaries; Charles River will retain the Exton bioanalysis and DMPK operations through sole ownership of the acquisition vehicle and certain Frontage subsidiaries, while Frontage’s remaining businesses will be transferred to Tigermed and Dr. Song Li (or his affiliates). Completion of the privatization is subject to approvals including resolutions at Tigermed’s general meeting, regulatory approvals, Frontage shareholder approval, and sanction of the scheme by the Grand Court of the Cayman Islands.

Birgit Girshick, Chief Executive Officer, commented, “The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market.” She said that as biologics and increasingly complex modalities become a larger part of development pipelines, clients are seeking scientific partners that can support programs from early development through the clinic, and that adding Frontage’s clinical bioanalysis expertise, scientific team, and client relationships will position Charles River to meet those needs. The acquisition will advance the company’s Pathway to Purpose strategy by expanding its presence in clinical bioanalysis and strengthening scientific leadership, she said, with the combined bioanalysis and DMPK offering providing a more integrated solution from preclinical through clinical testing.

The laboratories to be acquired provide a comprehensive suite of bioanalysis, biomarker, and DMPK testing services for large and small molecules, primarily supporting clinical development programs for biopharmaceutical clients. The planned acquisition includes a CLIA-certified central laboratory and encompasses two Exton sites that operate across approximately 150,000 square feet and employ approximately 340 people. The businesses represented approximately 40% of Frontage’s total 2025 revenue of $256.7 million. In 2025, the majority of Frontage’s bioanalysis revenue was generated during clinical development.

Charles River said the deal will expand capabilities in the high-growth clinical bioanalysis sector and complement existing strength in preclinical bioanalysis primarily for biologics and complex modalities. Currently, approximately 15% of Charles River’s bioanalysis revenue is generated from clinical-phase testing. The company said the bioanalysis market sector is expected to expand from approximately $6 billion in 2026 to approximately $8 to $9 billion in 2031, representing annual growth of 6% to 8%, with higher growth expected in biologics and complex modalities and clinical-phase testing. Biologics and complex modalities account for approximately 75% of Charles River’s bioanalysis revenue. Charles River expects revenue of the acquired businesses to grow at the projected bioanalysis sector growth rate over the next five years.

The transaction is expected to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter. The acquisition and associated fees are expected to be financed through Charles River’s credit facility and available cash. The acquired businesses are expected to be reported as part of Charles River’s DSA segment. J.P. Morgan and CICC are acting as joint financial advisers to the consortium.